HOME >> MEDICINE >> NEWS
New agreement questions NHS relation with industry

The Department of Health's new clinical trials agreement raises questions about the NHS's relation with the drug industry, says an editorial published on bmj.com today.

Following the tragedy of the TGN1412 trial, the Department of Health announced last month that a model clinical trials agreement has been finalised. This provides a template that can be used by all NHS trusts for any clinical trial, without modification.

But before embracing this agreement with open arms, we should examine what it actually says and what the deeper implications might be, warns Professor Michael Goodyear of Dalhousie University, Canada.

The agreement is the product of a unique consortium of industry, government, and academia, but other organisations, such as the Central Office for Research Ethics Committees, are not mentioned, despite being central to many issues covered in the agreement.

The agreement also applies only to contract research (commercial, industry sponsored trials usually directed towards pharmaceutical product licensing). It does not apply to phase I testing with healthy volunteers (as in TGN1412), to studies initiated by investigators, to trials in which the sponsor merely provides funding, or to research in non-NHS institutions.

While collaboration is admirable, we must realise that the development of a business model for research is a primary motivation behind this initiative, says Goodyear. As the guidance document states, the NHS is being "harnessed" in what is essentially a competitive model.

A surprising and disturbing element of the agreement relates to the crucial principles of transparency and accountability in research. Rather than incorporating and upholding the new and widely supported standards for an open research culture, the agreement has embedded an older and more problematic industry standard.

And, given that this agreement appears at a time when public trust in the drug industry
'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-020-738-36529
BMJ-British Medical Journal
16-Nov-2006


Page: 1 2

Related medicine news :

1. Heading to Siberia: UH signs agreement with Russian Academy of Sciences
2. Research agreement to advance new imaging technology
3. Access to science enhanced by new NIH-ASH agreement
4. Patent laws and US trade agreements are hindering access to HIV treatment
5. Stevens in agreement with Competitive Technologies to commercialize Stevens IP worldwide
6. GE Healthcare and St. Josephs Hospital and Medical Center, Phoenix announce research agreement
7. New licensing agreement to maximize AIDS drug development
8. AstraZeneca and M. D. Anderson Cancer Center form umbrella scientific collaboration agreements
9. Microbicide field praises agreement to license new AIDS drugs
10. Implementing European Space Policy: Key ESA/EC agreement on Earth Observation data signed today
11. Proteome Systems signs agreement with Prince Henrys Institute for Ovarian Cancer Diagnostic Test

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New agreement questions NHS relation with industry

(Date:7/31/2015)... ... July 31, 2015 , ... Precision Aesthetics is New York’s ... It was also the first provider of Exilis non-surgical fat reduction in New York. ... it has attracted a large International clientele. Many patients travel to New York ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... store run by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store ... of which are customizable. The best part: whenever a product is purchased, the ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Sculpted Contours ... the CoolSmooth PRO this week. Zeltiq Aesthetics released this new applicator in the ... January 2014 for treating the outer thighs. The original applicator required a 2 ...
(Date:7/31/2015)... FL (PRWEB) , ... July 31, 2015 , ... ... announced an important workshop at its new True North Conference Center. The medical ... so that the Jacksonville community may be more aligned in the effort to ...
(Date:7/31/2015)... View, CA (PRWEB) , ... July 31, 2015 , ... ... for the athletes, judges, media, and VIPs at the 2015 Vans US Open of ... organic coconut water that can claim “no added sugar” on the market, is a ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 2Health News:Lakeview Health Links Sex Trafficking and Addiction in Special Jacksonville Educational Workshop 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2
(Date:7/31/2015)... According to a new market research report ... Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air Displacement Plethysmography ... to 2019", published by MarketsandMarkets, the global Body Composition ... is estimated to grow to $1,425.7 Million by 2019, ... 2019. Browse 41 market data Tables ...
(Date:7/30/2015)... July 30, 2015 IRIDEX Corporation (NASDAQ: ... second quarter 2015 financial results after the market closes ... with the release, the Company will host a conference ... Eastern Time on Thursday, August 6, 2015 ... other business developments. Interested parties may access ...
(Date:7/30/2015)... 30, 2015  Unichem Pharmaceuticals ( USA ... Hydrochlorothiazide tablets 25 mg 1000-count bottle to the consumer ... measure due to the identification of a Clopidogrel tablet ... The risk associated with mistakenly taking a Clopidogrel ... probability of experiencing Clopidogrel,s side effects which include bleeding ...
Breaking Medicine Technology:Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4IRIDEX Announces Second Quarter 2015 Conference Call and Release Date 2Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
Cached News: